EP0781336A1 - Homologue de la kinase humaine activee par un mitogene (map) - Google Patents

Homologue de la kinase humaine activee par un mitogene (map)

Info

Publication number
EP0781336A1
EP0781336A1 EP96923586A EP96923586A EP0781336A1 EP 0781336 A1 EP0781336 A1 EP 0781336A1 EP 96923586 A EP96923586 A EP 96923586A EP 96923586 A EP96923586 A EP 96923586A EP 0781336 A1 EP0781336 A1 EP 0781336A1
Authority
EP
European Patent Office
Prior art keywords
smap
polypeptide
leu
expression
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96923586A
Other languages
German (de)
English (en)
Inventor
Phillip R. Hawkins
Janice Au-Young
Karl J. Guegler
Craig G. Wilde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharmaceuticals Inc filed Critical Incyte Pharmaceuticals Inc
Publication of EP0781336A1 publication Critical patent/EP0781336A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention is in the field of molecular biology; more particularly, the present invention describes a nucleic acid sequence and an amino acid sequence for a novel human MAP kinase homolog.
  • Mitogen-activated protein (MAP) kinases are a family of enzymes which regulate o intracellular signaling pathways. MAP kinases are important mediators of signal transduction from cell surfaces to nuclei via phosphorylation cascades. Several subgroups of MAP kinases have been defined and each manifests different substrate specificities and responds to various distinct extracellular stimuli. Thus, the MAP kinase signaling pathways represent common mechanisms for signal transduction by which different extracellular stimuli generate distinct 5 physiological responses inside cells (Egan SE and Weinberg RA (1993) Nature 365:781 -
  • MAP kinase signaling pathways have been defined in mammalian cells as well as in yeast.
  • the extracellular stimuli activating the MAP kinase signaling pathways include epidermal growth factor (EGF), ultraviolet light, hyperosmolar medium, heat 0 shock, endotoxic lipopolysaccharide (LPS), and pro-inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1 ).
  • EGF epidermal growth factor
  • LPS endotoxic lipopolysaccharide
  • pro-inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1 ).
  • TNF tumor necrosis factor
  • IL-1 interleukin-1
  • MAP kinases There are at least three subgroups of MAP kinases in mammalian cells (Derijard B et al 5 (1995) Science 267:682-5), and each subgroup is distinguished by a tripeptide sequence motif. They are extracellular signal-regulated protein kinase (ERK) characterized by Thr- Glu-Tyr, c-Jun amino-terminal kinase (JNK) characterized by Thr-Pro-Tyr, and p38 kinase characterized by Thr-Gly-Tyr.
  • the subgroups are activated by the dual phosphorylation of the threonine and tyrosine by MAP kinase kinases located upstream of the phosphorylation cascade. 0 Activated MAP kinases phosphorylate other effectors downstream ultimately leading to changes inside the cell.
  • MAP Kinase Subgroup ERK extracellular signal-regulated protein kinase
  • JNK
  • the ERK signal transduction pathway is activated via tyrosine kinase receptors on the plasma membrane of the cell.
  • EGF or other growth factors bind to the tyrosine receptors, 5 they, in turn, bind to noncatalytic, src homology (SH) adaptor proteins (SH2-SH3-SH2) and a guanine nucleotide releasing protein.
  • SH src homology
  • Ras proteins members of the large family of guanine nucleotide binding proteins (G-proteins).
  • the activated Ras proteins bind to a protein kinase C-Raf-1 and activate the Raf-1 proteins.
  • the activated Raf-1 kinase subsequently phosphorylates MAP kinase kinases which, in turn, activate MAP kinase ERKs by phosphorylating the threonine and tyrosine residues of the ERKs.
  • ERKs are proline-directed protein kinases which phosphorylate Ser/Thr-Pro motifs.
  • cytoplasmic phospholipase A2 cPLA2
  • transcription factor Elk-1 are substrates of the ERKs.
  • the ERKs phosphorylate Ser 505 of cPLA2 and cause an increase in its enzymatic activity resulting in an increased release of arachidonic acid and the formation of lysophospholipids from membrane phospholipids.
  • phosphorylation of the transcription factor Elk-1 by ELK ultimately results in increased transcriptional activity.
  • MAP Kinase Subgroup JNK MAP Kinase Subgroup JNK
  • the JNK signal transduction pathway can also be initiated by ultraviolet light, osmotic stress, and the pro-inflammatory cytokines, TNF and IL-1.
  • the Ras proteins may partially activate the JNK signal transduction pathway. JNKs phosphorylate Ser 63 and
  • p38 is a 41 kD protein containing 360 amino acids. Its dual phosphorylation is activated by the MAP kinase kinases, MKK3 and MKK4.
  • the p38 signal transduction pathway is also activated by heat shock, hyperosmolar medium, IL-1 or LPS endotoxin (Han J et al (1994) Science 265:808-811 ) produced by invading gram-negative bacteria.
  • the human body reacts to the invading bacteria by activating cells in the immune and inflammatory systems to initiating the systemic response called sepsis.
  • Sepsis is characterized by fever, chills, tachypnea, and tachycardia, and severe cases may result in septic shock which includes hypotension and multiple organ failure.
  • LPS may be thought of as a stress signal to the cell because it alters normal cellular processes by inducing the release of mediators such as TNF which has systemic effects.
  • CD14 is a glycosylphosphatidyl-inositol-anchored membrane glycoprotein which serves as an LPS receptor on the plasma membrane of cells of monocytic origin. The binding of LPS to CD14 causes rapid protein tyrosine phosphorylation of the 44- and 42- or 40-kD isoforms of MAP kinases. Although they bind LPS, these MAP kinase isoforms do not appear to belong to the p38 subgroup.
  • CSBPs cytokine suppressive binding proteins
  • CSAIDs cytokine- suppressive anti-inflammatory drugs
  • the subject invention provides a unique nucleotide sequence, herein designated in Iower case, smap (SEQ ID NO:1 ) which encodes a novel human MAP kinase protein, designated in upper case, SMAP (SEQ ID NO:2).
  • SMAP novel human MAP kinase protein
  • the cDNA encoding SMAP was identified and cloned using Incyte Clone No. 214915 from a stomach cDNA library.
  • the invention also relates to the use of the nucleotide and amino acid sequences of SMAP, or its variants, in the diagnosis and treatment of activated or inflamed cells and/or tissues associated with its expression.
  • aspects of the invention include the antisense DNA of smap; cloning or expression vectors containing smap; host cells transformed with the expression vector; a method for the production and recovery of purified SMAP from host cells; and purified protein, SMAP, which can be used to produce antibodies or identify inhibitors of the protein.
  • Figure 1A and 1 B display the alignment of the nucleotide sequence (SEQ ID NO:1 ) and amino acid sequence (SEQ ID NO:2) for human MAP kinase homolog produced using MacDNAsis software (Hitachi Software Engineering Co Ltd).
  • Figure 2 shows the amino acid alignment between SMAP and mouse kinase, GenBank 531 125 (locus MMU10871 ; Han et al. (1994) Science 265:808-810).
  • Figure 3 shows the amino acid alignment between SMAP and the closely related mitogen activated protein kinase homolog, GenBank 603917 (locus HUMCSBP1 ; Lee et al (1994) Nature 372:739-746). Alignments for Figs. 2 and 3 were produced using the INHERITTM 670 Sequence Analysis System (Applied Biosystems, Foster City CA).
  • mapping refers to a gene, cDNA or nucleic acid sequence for the novel human MAP kinase homolog while the uppercase letters, “SMAP”, refer to the protein sequence encoded by human MAP kinase homolog.
  • the present invention provides a unique nucleotide sequence identifying a novel MAP kinase homolog from human stomach cell, SEQ ID NO:1.
  • the coding region of SEQ ID NO:1 begins at nucleotide 58 and ends at nucleotide 1156. Since SMAP is specifically involved with protective cell signaling processes, the nucleic acid, protein, and antibodies are useful in the study, diagnosis and treatment of conditions which affect the stomach such as gastritis, ulcers, viral and bacterial infections, neoplasms and the like.
  • oligonucleotide is a stretch of nucleotide residues which has a sufficient number of bases to be used as an oligomer, amplimer or probe in a polymerase chain reaction (PCR). Oligonucleotides are prepared from genomic or cDNA sequence and are used to amplify, confirm, or reveal the presence of smap DNA or RNA in a particular cell or tissue. Oligonucleotides or oligomers comprise portions of a DNA sequence having at least about 10 nucleotides and as many as about 50 nucleotides, preferably about 15 to 30 nucleotides.
  • Probes are nucleic acid sequences of variable length, preferably between 10 and 6,000 nucleotides, which may be chemically synthesized, naturally occurring, or recombinant single- or double-stranded nucleic acids. They are useful in the qualitative or quantitative detection of the same, a similar, or a complementary nucleic acid sequence.
  • Reporter molecules are chemical moieties used for labelling a nucleic or amino acid sequence. They include, but are not limited to, radionuclides, enzymes, fluorescent, chemi- luminescent, or chromogenic agents. Reporter molecules associate with, establish the presence of, and may allow quantification of a particular nucleic or amino acid sequence.
  • a "portion" or “fragment” of a polynucleotide or nucleic acid comprises all or any part of the nucleotide sequence having fewer nucleotides than about 6 kb, preferably fewer than about 1 kb which can be used as a probe.
  • probes may be labeled with reporter molecules using nick translation, Klenow fill-in reaction, PCR or other methods well known in the art. After pretesting to optimize reaction conditions and to eliminate false positives, nucleic acid probes may be used in Southern, northern or in situ hybridizations to determine whether DNA or RNA encoding the protein is present in a biological sample, cell type, tissue, organ or organism.
  • Recombinant nucleotide variants are polynucleotides which encode SMAP. They may be synthesized by making use of the "redundancy" in the genetic code. Various codon substitutions, such as the silent changes which produce specific restriction sites or codon usage-specific mutations, may be introduced to optimize cloning into a plasmid or viral vector or expression in a particular prokaryotic or eukaryotic host system, respectively. "Linkers" are synthesized palindromic oligomers which create internal restriction endonuclease sites.
  • Codon genes are polynucleotides which may be constructed by introducing all or part of the nucleotide sequence of this invention into a vector containing additional nucleic acid sequence(s). Such sequences may be expected to change any one (or more than one) of the following SMAP characteristics: cellular location, distribution, ligand-binding affinities, interchain affinities, degradation/turnover rate, signalling, etc.
  • Active refers to those forms, fragments, or domains of any SMAP polypeptide which display the biologic and/or immunogenic activities of any naturally occurring SMAP.
  • Naturally occurring SMAP refers to a polypeptide produced by cells which have not been genetically engineered and specifically contemplates various polypeptides which arise from post-translational modifications. Such modifications of the polypeptide include but not limited to acetylation, carboxylation, glycosylation, phosphorylation, iipidation and acylation. “Derivative” refers to those polypeptides which have been chemically modified by such techniques as ubiquitination, labelling (see above), pegylation (derivatization with polyethylene glycol), and chemical insertion or substitution of amino acids such as ornithine which do not normally occur in human proteins.
  • Recombinant polypeptide variant refers to any polypeptide which differs from naturally occurring SMAP by amino acid insertions, deletions and/or substitutions, created using recombinant DNA techniques. Guidance in determining which amino acid residues may be replaced, added or deleted without abolishing activities of interest may be found by comparing the sequence of SMAP with that of related polypeptides and minimizing the number of amino acid sequence changes made in highly conserved regions.
  • substitutions are defined as one for one amino acid replacements. They are conservative in nature when the substituted amino acid has similar structural and/or chemical properties. Examples of conservative replacements are substitution of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.
  • Amino acid "insertions” or “deletions” are changes to or within an amino acid sequence. They typically fall in the range of about 1 to 5 amino acids. The variation allowed in a particular amino acid sequence may be experimentally determined by producing the peptide synthetically or by systematically making insertions, deletions, or substitutions of nucleotides in the smap sequence using recombinant DNA techniques.
  • a “signal or leader sequence” is a short amino acid sequence which or can be used, when desired, to direct the polypeptide through a membrane of a cell. Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous sources by recombinant DNA techniques.
  • oligopeptide is a short stretch of amino acid residues and may be expressed from an oligonucleotide. It may be functionally equivalent to and the same length as (or considerably shorter than) a "fragment,” “portion,” or “segment” of a polypeptide. Such sequences comprise a stretch of amino acid residues of at least about 5 amino acids and often about 17 or more amino acids, typically at least about 9 to 13 amino acids, and of sufficient length to display biologic and/or immunogenic activity.
  • inhibitor is a substance which retards or prevents a chemical or physiological reaction or response. Common inhibitors include but are not limited to antisense molecules, antibodies, and antagonists.
  • a "standard” is a quantitative or qualitative measurement for comparison. It is based on a statistically appropriate number of normal samples and is created to use as a basis of comparison when performing diagnostic assays, running clinical trials, or following patient treatment profiles.
  • Animal as used herein may be defined to include human, domestic (cats dogs, etc.), agricultural (cows, horses, sheep, etc) or test species (mouse, rat, rabbit, etc).
  • Kinase nucleotide sequences have numerous applications in techniques known to those skilled in the art of molecular biology. These techniques include the use of kinase sequences as hybridization probes, for chromosome and gene mapping, in the design of oligomers for PCR, and in the production of sense or antisense nucleic acids, their chemical analogs and the like. These examples are well known and are not intended to be limiting. Furthermore, the nucleotide sequences disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known such as the triplet genetic code, specific base pair interactions, etc.
  • kinase-encoding nucleotide sequences may be produced and some of these will bear only minimal homology to the endogenous sequence of any known and naturally occurring kinase.
  • This invention has specifically contemplated each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring kinases, and all such variations are to be considered as being specifically disclosed.
  • nucleotide sequences which encode a specific kinase and its derivatives or variants are preferably capable of identifying the nucleotide sequence of the naturally occurring kinase under optimized conditions, it may be advantageous to produce smap possessing a substantially different codon usage. Codons can be selected to increase the rate of peptide expression in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding the kinase without altering the encoded amino acid sequence include the production of RNA transcripts having more desirable properties, such as a longer half-life, than transcripts produced from the naturally occurring sequence.
  • Nucleotide sequences encoding a kinase may be joined to a variety of other nucleotide sequences by means of well established recombinant DNA techniques (Sambrook J et al (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor NY; or Ausubel FM et al (1989) Current Protocols in Molecular Biology, John Wiley & Sons,
  • Useful nucleotide sequences for joining to the kinase include an assortment of cloning vectors such as plasmids, cosmids, lambda phage derivatives, phagemids, and the like.
  • Vectors of interest include vectors for replication, expression, probe generation, sequencing, and the like. In general, vectors of interest may contain an origin of replication functional in at least one organism, convenient restriction endonuclease sensitive sites, and selectable markers for one or more host cell systems.
  • kinase hybridization probes which are capable of hybridizing with naturally occurring nucleotide sequences encoding kinases.
  • the stringency of the hybridization conditions will determine whether the probe identifies only nucleotide sequence of that specific kinase or sequences of closely related molecules. If such probes are used for the detection of related kinase encoding sequences, they should preferably contain at least 50% of the nucleotides from any of the sequence presented here.
  • Hybridization probes of the subject invention may be derived from the nucleotide sequences of the SEQ ID NO:1 or from an isolated genomic sequence including untranslated regions such as promoters, enhancers and introns.
  • Such hybridization probes may be labeled with reporter molecules.
  • PCR as described US Patent Nos. 4,683,195; 4,800,195; and 4,965,188 provides additional uses for oligonucleotides based upon the kinase nucleotide sequence.
  • oligomers may be of recombinant origin, chemically synthesized, or a mixture of both. Oligomers may comprise two nucleotide sequences employed under optimized conditions for tissue specific identification or diagnostic use. The same two oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for identification of closely related DNA or RNA sequences.
  • DNA This method was developed to allow a single researcher to process multiple genes (up to 20 or more) at a time and to obtain an extended (possibly full-length) sequence within 6-10 days. It replaces current methods which use labeled probes to screen libraries and allow one researcher to process only about 3-5 genes in 14-40 days.
  • primers are designed and synthesized based on a known partial sequence.
  • step 2 which takes about six to eight hours, the sequence is extended by PCR amplification of a selected library.
  • Steps 3 and 4 which take about one day, are purification of the amplified cDNA and its ligation into an appropriate vector, respectively.
  • Step 5 which takes about one day, involves transforming and growing up host bacteria.
  • step 6 which takes approximately five hours, PCR is used to screen bacterial clones for extended sequence.
  • the final steps which take about one day, involve the preparation and sequencing of selected clones. If the full length cDNA has not been obtained, the entire procedure is repeated using either the original library or some other preferred library.
  • the preferred library may be one that has been size-seiected to include only larger cDNAs or may consist of single or combined commercially available libraries, eg. lung, liver, heart and brain from Gibco/BRL (Gaithersburg MD).
  • the cDNA library may have been prepared with oligo d(T) or random primers.
  • the advantage of using random primed libraries is that they will have more sequences which contain 5' ends of genes.
  • a randomly primed library may be particularly useful if an oligo d(T) library does not yield a complete gene. Obviously, the larger the protein, the less likely it is that the complete gene will be found in a single plasmid.
  • RNA polymerase such as T7 or SP6 and labeled nucleotides.
  • T7 or SP6 RNA polymerase
  • RNA polymerase such as T7 or SP6
  • T7 or SP6 RNA polymerase
  • synthetic chemistry may be used to introduce mutations into the nucleotide sequence. Alternately, a portion of sequence in which a mutation is desired can be synthesized and recombined with a portion of an existing genomic or recombinant sequence.
  • the kinase nucleotide sequences can be used individually, or in panels, in an assay to detect inflammation or disease associated with abnormal levels of kinase expression.
  • the nucleotide sequence is added to a fluid, cell or tissue sample from a patient under hybridizing conditions. After an incubation period, the sample is washed with a compatible fluid which optionally contains a reporter molecule which will bind the specific nucleotide. After the compatible fluid is rinsed off, the reporter molecule is quantitated and compared with a standard for that fluid, cell or tissue. If kinase expression is significantly different from the standard, the assay indicates the presence of inflammation or disease.
  • This same assay combining a sample with the nucleotide sequence, is applicable in evaluating the efficacy of a particular therapeutic treatment regime. It may be used in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.
  • the cDNA for human MAP kinase can also be used to design hybridization probes for mapping the native genomic sequence.
  • the sequence may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. These include in situ hybridization to chromosomal spreads (Verma et al (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York City), flow-sorted chromosomal preparations, or artificial chromosome constructions such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions or single chromosome cDNA libraries.
  • AT ataxia telangiectasia
  • genomic region for example, AT to 1 1 q22-23 (Gatti et al (1988) Nature 336:577-580)
  • any sequences mapping to that area may represent genes for further investigation of AT.
  • the nucleotide sequence of the subject invention may also be used to detect differences in gene sequence between normal and carrier or affected individuals. Nucleotide sequences encoding a particular kinase may be used to produce purified oligopeptide using well known methods of recombinant DNA technology.
  • oligopeptide may be expressed in a variety of host cells, either prokaryotic or eukaryotic. Host cells may be from the same species from which the nucleotide sequence was derived or from a different species. Advantages of producing an oligonucleotide by recombinant DNA technology include obtaining adequate amounts of the protein for purification and the availability of simplified purification procedures.
  • Cells transformed with a kinase nucleotide sequence may be cultured under conditions suitable for the expression and recovery of the oligopeptide from cell culture.
  • the oligopeptide produced by a recombinant cell may be secreted or may be contained intracellularly depending on the sequence and the genetic construction used. In general, it is more convenient to prepare recombinant proteins in secreted form. Purification steps vary with the production process and the particular protein produced. Often an oligopeptide can be produced from a chimeric nucleotide sequence. This is accomplished by Iigating the kinase sequence to a nucleic acid sequence encoding a polypeptide domain which will facilitate protein purification (Kroll DJ et al (1993) DNA Cell Biol 12:441 -53).
  • kinase fragments may be produced by direct peptide synthesis using solid-phase techniques (Stewart et al (1969) Solid-Phase Peptide Synthesis, WH Freeman Co, San Francisco CA; Merrifield J (1963) J Am Chem Soc
  • kinase sequence may be mutated during chemical synthesis, combined using chemical methods with other kinase sequence(s), and used in an appropriate vector and host cell to produce a polypeptide.
  • amino acid sequence or oligopeptide used for antibody induction does not require biological activity, it must be antigenic and consist of at least five amino acids and preferably at least 10 amino acids. Short stretches of amino acid sequence may be fused with those of another protein such as keyhole limpet hemocyanin, and the chimeric peptide used for antibody production.
  • Antibodies specific for SMAP may be produced by inoculation of an appropriate animal with an antigenic fragment of the peptide.
  • An antibody is specific for SMAP if it is produced against an epitope of the polypeptide and binds to at least part of the natural or recombinant protein.
  • Antibody production includes not only the stimulation of an immune response by injection into animals, but also analogous processes such as the production of synthetic antibodies, the screening of recombinant immunoglobulin libraries for specific-binding molecules (Orlandi R et al (1989) PNAS 86:3833-3837, or Huse WD et al (1989) Science 256:1275-1281 ), or the in vitro stimulation of lymphocyte populations.
  • Current technology (Winter G and Milstein C (1991 ) Nature 349:293-299) provides for a number of highly specific binding reagents based on the principles of antibody formation. These techniques may be adapted to produce molecules which specifically bind SMAPs.
  • the partial cDNA sequence for the human MAP kinase homolog was initially identified in Incyte Clone 214915 among the sequences comprising the human stomach cell library, Patent Application Serial Number 08/385,268, filed 7 February 1995, disclosed herein by reference.
  • the normal stomach tissue used for this library was obtained from the Keystone
  • RNA was sent to Stratagene (La Jolla CA) and oligo d(T) priming was used to prepare the cDNA library. Synthetic linkers were ligated onto the cDNA molecules, and they were inserted into the Uni-ZAPTM vector system (Stratagene). I I Isolation of cDNA Clones
  • the phagemid forms of individual cDNA clones were obtained by the ]n vivo excision process, in which the host bacterial strain was co-infected with both the library phage and an f1 helper phage.
  • Polypeptides or enzymes derived from both the library-containing phage and the helper phage nicked the DNA, initiated new DNA synthesis from defined sequences on the target DNA, and created a smaller, single stranded circular phagemid DNA molecule that included all DNA sequences of the pBluescript phagemid and the cDNA insert.
  • the phagemid DNA was released from the cells, purified, and used to reinfect fresh host cells (SOLR, Stratagene) where double-stranded phagemid DNA was produced. Phagemid DNA was purified using the QIAWELL-8TM Plasmid Purification System
  • the kit has a 96-well format and provides enough reagents for 960 purifications.
  • the recommended protocol is employed except for the following changes.
  • each of the 96 wells is filled with 1 ml of sterile terrific broth (LIFE TECHNOLOGIESTM, Gaithersburg MD) containing carbenicillin at 25 mg/L and glycerol at 0.4%.
  • the bacteria are introduced into the wells, cultured for 24 hours and lysed with 60 ⁇ l of lysis buffer.
  • the block is centrifuged at 2900 rpm for 5 minutes and then the contents of the block are added to the primary filter plate.
  • An optional step of adding isopropanol to the TRIS buffer is not routinely performed. Following the last step in the protocol, samples are transferred to a Beckman 96-well block for storage.
  • the cDNA inserts from random isolates of the stomach library were sequenced in part.
  • Methods for DNA sequencing are well known in the art and employ such enzymes as SEQUENASE® (US Biochemical Corp, Cleveland, OH) or Taq polymerase.
  • SEQUENASE® US Biochemical Corp, Cleveland, OH
  • Taq polymerase a polymerase that catalyzes the PCR amplification of DNA.
  • Methods to extend the DNA from an oligonucleotide primer annealed to the DNA template of interest have been developed for the use of both single- and double-stranded templates.
  • the chain termination reaction products were separated using electrophoresis and urea-acrylamide gels and detected either by autoradiography with radionuclide-labeled precursors or by fluorescent or chromogenic labelling. Recent improvements in mechanized reaction preparation, sequencing and analysis using the latter methods have permitted expansion in the number of sequences determined per day.
  • the machines used in these processes include the Catalyst 800, Hamilton Micro Lab 2200 (Hamilton, Reno NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown MA) and the Applied Biosystems 377 and 373 DNA sequencers.
  • Peptide and protein sequence homologies were ascertained using the INHERITTM 670 Sequence Analysis System in a way similar to that used in DNA sequence homologies. Pattern Specification Language and parameter windows were used to search protein databases for sequences containing regions of homology which were scored with an initial value. Dot-matrix homology plots were examined to distinguish regions of significant homology from chance matches.
  • BLAST which stands for Basic Local Alignment Search Tool, is used to search for local sequence alignments (Altschul SF (1993) J Mol Evol 36:290-300; Altschul, SF et al (1990) J Mol Biol 215:403-10). BLAST produces alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST is especially useful in determining exact matches or in identifying homologs. Whereas it is ideal for matches which do not contain gaps, it is inappropriate for performing motif-style searching.
  • the fundamental unit of BLAST algorithm output is the High-scoring Segment Pair (HSP).
  • An HSP consists of two sequence fragments of arbitrary but equal lengths whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user.
  • the BLAST approach is to look for HSPs between a query sequence and a database sequence, to evaluate the statistical significance of any matches found, and to report only those matches which satisfy the user-selected threshold of significance.
  • the parameter E establishes the statistically significant threshold for reporting database sequence matches. E is interpreted as the upper bound of the expected frequency of chance occurrence of an HSP (or set of HSPs) within the context of the entire database search. Any database sequence whose match satisfies E is reported in the program output.
  • Incyte 214915 was extended to full length using a modified XL-PCR (Perkin Elmer) procedure. Primers were designed based on the known sequence; one primer was synthesized to initiate extension in the antisense direction (XLR) and the other to extend sequence in the sense direction (XLF). The primers allowed the sequence to be extended "outward" generating amplicons containing new, unknown nucleotide sequence for the gene of interest.
  • the primers were designed using Oligo 4.0 (National Biosciences Inc, Plymouth MN) to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.
  • XL-PCR kit By following the instructions for the XL-PCR kit and thoroughly mixing the enzyme and reaction mix, high fidelity amplification is obtained. Beginning with 25 pMol of each primer and the recommended concentrations of all other components of the kit, PCR was performed using the Peltier thermal cycler (MJ PTC200; MJ Research, Watertown MA) and the following parameters: Step 1 94° C for 60 sec (initial denaturation) Step 2 94° C for 15 sec
  • Step 4 68° C for 7 min
  • Step 5 Repeat step 2-4 for 15 additional times
  • Step 6 94° C for 15 sec
  • Step 7 65° C for 1 min
  • Step 8 68° C for 7 min + 15 sec/cycle
  • Step 9 Repeat step 6-8 for 11 additional times
  • Step 1 1 4° C (and holding) At the end of 28 cycles, 50 ⁇ l of the reaction mix was removed; and the remaining reaction mix was run for an additional 10 cycles as outlined below:
  • Step 1 94° C for 15 sec
  • Step 2 65° C for 1 min
  • Step 3 68° C for (10 min + 15 sec)/cycle
  • Step 4 Repeat step 1 -3 for 9 additional times
  • Klenow enzyme was used to trim single-stranded, nucleotide overhangs creating blunt ends which facilitated religation and cloning. 5 After ethanol precipitation, the products were redissolved in 13 ⁇ l of ligation buffer.
  • Step 1 94° C for 60 sec
  • Step 2 94° C for 20 sec
  • Step 4 72° C for 90 sec 5
  • Step 5 Repeat steps 2-4 for an additional 29 times Step 6 72° C for 180 sec
  • Figure 1 shows the nucleotide and amino acid sequences for human MAP kinase homolog.
  • SMAP SEQ ID NO: 2
  • MMU10871 Gl 531125, SEQ ID NO:3
  • HUMCSBP1 GI 603917
  • oligonucleotides from genomic or cDNAs, comprising either the sense or the antisense strand of the cDNA sequence is used in vitro or in vivo to inhibit expression. Such technology is now well known in the art, and oligonucleotides or other fragments are designed from various locations along the sequences.
  • the gene of interest is turned off in the short term by transfecting a cell or tissue with expression vectors which flood the cell with sense or antisense sequences until all copies of the vector are disabled by endogenous nucleases.
  • smap is accomplished by subcloning the cDNAs into appropriate expression vectors and transfecting the vectors into an appropriate expression hosts.
  • the cloning vector previously used for the generation of the tissue library also provide for direct expression of smap sequences in J esil Upstream of the cloning site, this vector contains a promoter for ⁇ -galactosidase, followed by sequence containing the amino-terminal Met and the subsequent 7 residues of ⁇ -galactosidase. immediately following these eight residues is an engineered bacteriophage promoter useful for artificial priming and transcription and a number of unique restriction sites, including Eco Rl, for cloning.
  • Induction of the isolated, transfected bacterial strain with IPTG using standard methods produces a fusion protein corresponding to the first seven residues of ⁇ -galactosidase, about 5 to 15 residues which correspond to linker, and the peptide encoded within the cDNA. Since cDNA clone inserts are generated by an essentially random process, there is one chance in three that the included cDNA lies in the correct frame for proper translation. If the cDNA is not in the proper reading frame, it is obtained by deletion or insertion of the appropriate number of bases by well known methods including in vitro mutagenesis, digestion with exonuclease III or mung bean nuclease, or oligonucleotide linker inclusion.
  • the smap cDNA is shuttled into other vectors known to be useful for expression of protein in specific hosts.
  • Oligonucleotide linkers containing cloning sites as well as a segment of DNA sufficient to hybridize to stretches at both ends of the target cDNA (25 bases) is synthesized chemically by standard methods. These primers are then used to amplify the desired gene segments by PCR. The resulting new gene segments are digested with appropriate restriction enzymes under standard conditions and isolated by gel electrophoresis. Alternately, similar gene segments are produced by digestion of the cDNA with appropriate restriction enzymes and filling in the missing gene segments with chemically synthesized oligonucleotides.
  • Segments of the coding sequence from more than one gene are ligated together and cloned in appropriate vectors to optimize expression of recombinant sequence.
  • Suitable expression hosts for such chimeric molecules include but are not limited to mammalian cells such as Chinese Hamster Ovary (CHO) and human 293 cells, insect cells such as Sf9 cells, yeast cells such as Saccharomyces cerevisiae. and bacteria such as E. coli.
  • a useful expression vector includes an origin of replication to allow propagation in bacteria and a selectable marker such as the ⁇ -lactamase antibiotic resistance gene to allow selection in bacteria.
  • the vectors include a second selectable marker such as the neomycin phosphotransferase gene to allow selection in transfected eukaryotic host cells.
  • Vectors for use in eukaryotic expression hosts usually require RNA processing elements such as 3' polyadenylation sequences if such are not part of the cDNA of interest.
  • the vector contains promoters or enhancers which increase gene expression.
  • promoters are host specific and include MMTV, SV40, and metallothionine promoters for CHO ceils; trp, lac, tac and T7 promoters for bacterial hosts; and alpha factor, alcohol oxidase and PGH promoters for yeast.
  • Transcription enhancers such as the rous sarcoma virus (RSV) enhancer, is used in mammalian host cells. Once homogeneous cultures of recombinant cells are obtained through standard culture methods, large quantities of recombinantly produced SMAP are recovered from the conditioned medium and analyzed using chromatographic methods known in the art.
  • RSV rous sarcoma virus
  • SMAP is expressed as a chimeric protein with one or more additional polypeptide domains added to facilitate protein purification.
  • additional polypeptide domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA).
  • the inclusion of a cleavable linker sequence such as Factor XA or enterokinase (Invitrogen) between the purification domain and the smap sequence is useful to facilitate purification of SMAP.
  • denatured protein from the reverse phase HPLC separation is obtained in quantities up to 75 mg. This denatured protein is used to immunize mice or rabbits using standard protocols; about 100 micrograms are adequate for immunization of a mouse, while up to 1 mg might be used to immunize a rabbit.
  • the denatured protein is radioiodinated and used to screen potential murine B-cell hybridomas for those which produce antibody. This procedure requires only small quantities of protein, such that 20 mg would be sufficient for labeling and screening of several thousand clones.
  • the amino acid sequence of SMAP is analyzed to determine regions of high immunogenicity. Oligopeptides comprising appropriate hydrophilic regions are synthesized and used in suitable immunization protocols to raise antibodies. Analysis to select appropriate epitopes is described by Ausubel FM et al (supra).
  • the optimal amino acid sequences for immunization are usually at the C-terminus, the N-terminus and those intervening, hydrophilic regions of the polypeptide which are likely to be exposed to the external environment when the protein is in its natural conformation.
  • selected peptides typically, about 15 residues in length, are synthesized using an Applied Biosystems Peptide Synthesizer Model 431 A using fmoc-chemistry and coupled to keyhole limpet hemocyanin (KLH, Sigma) by reaction with M-maleimidobenzoyl-N- hydroxysuccinimide ester (MBS; Ausubel FM et al, supra). If necessary, a cysteine is introduced at the N-terminus of the peptide to permit coupling to KLH. Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant.
  • the resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1 % bovine serum albumin, reacting with antisera, washing and reacting with labeled (radioactive or fluorescent), affinity purified, specific goat anti-rabbit IgG.
  • Hybridomas are prepared and screened using standard techniques. Hybridomas of interest are detected by screening with labeled SMAP to identify those fusions producing the monoclonal antibody with the desired specificity.
  • wells of plates FAST; Becton-Dickinson, Palo Alto, CA
  • affinity purified, specific rabbit anti-mouse (or suitable anti-species Ig) antibodies at 10 mg/ml.
  • the coated wells are blocked with 1% BSA, washed and incubated with supernatants from hybridomas. After washing the wells are incubated with labeled SMAP at 1 mg/ml. Supernatants with specific antibodies bind more labeled SMAP than is detectable in the background.
  • clones producing specific antibodies are expanded and subjected to two cycles of cloning at limiting dilution (1 cell/3 wells).
  • Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from mouse ascitic fluid by affinity chromatography on Protein A.
  • Monoclonal antibodies with affinities of at least 10 8 /M, preferably 10 9 to 10 10 or stronger, are typically made by standard procedures as described in Harlow and Lane (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; and in Goding (1986) Monoclonal Antibodies: Principles and Practice, Academic Press, New York City, both incorporated herein by reference.
  • SMAP antibodies are useful for investigation of various forms of stomach conditions characterized by differences in the amount or distribution of SMAP.
  • SMAP from the human stomach library appears to be upreguiated in its characteristic involvement in immune protection or defense.
  • Diagnostic tests for SMAP include methods utilizing the antibody and a label to detect SMAP in human body fluids, membranes, cells, tissues or extracts of such.
  • the polypeptides and antibodies of the present invention are used with or without modification. Frequently, the polypeptides and antibodies are labeled by joining them, either covalently or noncovalently, with a substance which provides for a detectable signal.
  • labels and conjugation techniques are known and have been reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent agents, chemiluminescent agents, magnetic particles and the like. Patents teaching the use of such labels include US Patent Nos.
  • a variety of protocols for measuring soluble or membrane-bound SMAP, using either polyclonal or monoclonal antibodies specific for the protein, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS).
  • ELISA enzyme-linked immunosorbent assay
  • RIA radioimmunoassay
  • FACS fluorescent activated cell sorting
  • a two-site monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on SMAP is preferred, but a competitive binding assay may be employed. These assays are described, among other places, in Maddox, DE et al (1983, J Exp Med 158:121 1 ).
  • Native or recombinant SMAP is purified by immunoaffinity chromatography using antibodies specific for SMAP.
  • an immunoaffinity column is constructed by covalently coupling the anti-SMAP antibody to an activated chromatographic resin.
  • Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB
  • monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated Sepharose (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.
  • a chromatographic resin such as CnBr-activated Sepharose (Pharmacia LKB Biotechnology).
  • Such immunoaffinity columns are utilized in the purification of SMAP by preparing a fraction from cells containing SMAP in a soluble form. This preparation is derived by solubilization of whole cells or of a subcellular fraction obtained via differential centrifugation (with or without addition of detergent) or by other methods well known in the art.
  • soluble SMAP containing a signal sequence is secreted in useful quantity into the medium in which the ceils are grown.
  • a soluble SMAP-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of SMAP (eg, high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions that disrupt antibody/SMAP binding (eg, a buffer of pH 2-3 or a high concentration of a chaotrope such as urea or thiocyanate ion), and SMAP is collected.
  • SMAP eg, high ionic strength buffers in the presence of detergent
  • SMAP or binding fragments thereof in any of a variety of drug screening techniques.
  • the polypeptide or fragment employed in such a test is either free in solution, affixed to a solid support, borne on a cell surface or located intracellularly.
  • One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, are used for standard binding assays.
  • One measures for example, the formation of complexes between SMAP and the agent being tested. Alternatively, one can examine the diminution in complex formation between SMAP and a receptor caused by the agent being tested.
  • the present invention provides methods of screening for drugs or any other agents which affect signal transduction. These methods comprise contacting such an agent with SMAP polypeptide or a fragment thereof and assaying (i) for the presence of a complex between the agent and the SMAP polypeptide or fragment, or (ii) for the presence of a complex between the SMAP polypeptide or fragment and the cell, by methods well known in the art.
  • the SMAP polypeptide or fragment is typically labeled. After suitable incubation, free SMAP polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to SMAP or to interfere with the SMAP and agent complex.
  • This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding SMAP specifically compete with a test compound for binding to SMAP polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic determinants with SMAP.
  • the goal of rational drug design is to produce structural analogs of biologically active polypeptides of interest or of small molecules with which they interact, e.g., agonists, antagonists, or inhibitors. Any of these examples are used to fashion drugs which are more active or stable forms of the polypeptide or which enhance or interfere with the function of a polypeptide in vivo (Hodgson J (1991 ) Bio/Technology 9:19-21 , incorporated herein by reference).
  • the three-dimensional structure of a protein of interest, or of a protein-inhibitor complex is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches.
  • Both the shape and charges of the polypeptide must be ascertained to elucidate the structure and to determine active site(s) of the molecule. Less often, useful information regarding the structure of a polypeptide is gained by modeling based on the structure of homologous proteins. In both cases, relevant structural information is used to design efficient inhibitors. Useful examples of rational drug design include molecules which have improved activity or stability as shown by Braxton S and Wells JA (1992 Biochemistry 31 :7796-7801 ) or which act as inhibitors, agonists, or antagonists of native peptides as shown by Athauda SB et al (1993 J Biochem 113:742-746), incorporated herein by reference.
  • a target-specific antibody selected by functional assay, as described above, and then to solve its crystal structure.
  • This approach in principle, yields a pharmacore upon which subsequent drug design is based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids is expected to be an analog of the original receptor. The anti-id is then used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides then act as the pharmacore.
  • anti-ids anti-idiotypic antibodies
  • polypeptide is made available to perform such analytical studies as X-ray crystallography.
  • knowledge of the SMAP amino acid sequence provided herein provides guidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography.
  • the inventive purified SMAP is a research tool for identification, characterization and purification of interacting or signal transduction pathway proteins.
  • Radioactive labels are incorporated into SMAP by various methods known in the art and used to capture either soluble or membrane-bound molecules.
  • a preferred method involves labeling the primary amino groups in SMAP with 125 l Bolton-Hunter reagent (Bolton, AE and Hunter, WM (1973) Biochem J 133: 529). This reagent has been used to label various molecules without concomitant loss of biological activity (Hebert CA et al (1991 ) J Biol Chem 266: 18989; McColl S et al (1993) J Immunol 150:4550-4555).
  • Membrane-bound molecules are incubated with the labeled SMAP molecules, washed to removed unbound molecules, and the SMAP complex is quantified. Data obtained using different concentrations of SMAP are used to calculate values for the number, affinity, and association of SMAP complex.
  • Labeled SMAP is also useful as a reagent for the purification of molecules with which SMAP interacts.
  • SMAP is covalently coupled to a chromatography column. Cells and their membranes are extracted, SMAP is removed and various SMAP-free subcomponents are passed over the column. Molecules bind to the column by virtue of their SMAP affinity.
  • the SMAP-complex is recovered from the column, dissociated and the recovered molecule is subjected to N-terminal protein sequencing. This amino acid sequence is then used to identify the captured molecule or to design degenerate oligonucleotide probes for cloning its gene from an appropriate cDNA library.
  • antibodies are raised against SMAP, specifically monoclonal antibodies.
  • the monoclonal antibodies are screened to identify those which inhibit the binding of labeled SMAP. These monoclonal antibodies are then used in affinity purification or expression cloning of associated molecules.
  • SMAP molecule are identified by a sizing technique such as size exclusion chromatography or density gradient centrifugation and are purified by methods known in the art.
  • the soluble binding protein(s) are subjected to N-terminal sequencing to obtain information sufficient for database identification, if the soluble protein is known, or for cloning, if the soluble protein is unknown.
  • TSTs are formulated in a nontoxic, inert, pharmaceutically acceptable aqueous carrier medium preferably at a pH of about 5 to 8, more preferably 6 to 8, although the pH may vary according to the characteristics of the antibody, inhibitor, or antagonist being formulated and the condition to be treated. Characteristics of TSTs include solubility of the molecule, half-life and antigenicity/immunogenicity; these and other characteristics aid in defining an effective carrier. Native human proteins are preferred as TSTs, but organic or synthetic molecules resulting from drug screens are equally effective in particular situations.
  • TSTs are delivered by known routes of administration including but not limited to topical creams and gels; transmucosal spray and aerosol; transdermal patch and bandage; injectable, intravenous and lavage formulations; and orally administered liquids and pills particularly formulated to resist stomach acid and enzymes.
  • routes of administration including but not limited to topical creams and gels; transmucosal spray and aerosol; transdermal patch and bandage; injectable, intravenous and lavage formulations; and orally administered liquids and pills particularly formulated to resist stomach acid and enzymes.
  • the particular formulation, exact dosage, and route of administration are determined by the attending physician and vary according to each specific situation.
  • Such determinations are made by considering multiple variables such as the condition to be treated, the TST to be administered, and the pharmacokinetic profile of the particular TST.
  • TST formulations might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular TST.
  • Normal dosage amounts vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration.
  • Guidance as to particular dosages and methods of delivery is provided in the literature. See US Patent No. 4,657,760; 5,206,344; or 5,225,212.
  • Those skilled in the art employ different formulations for different TSTs.
  • Administration to cells such as nerve cells necessitates delivery in a manner different from that to other cells such as vascular endothelial cells.
  • conditions or diseases which trigger defensive signal transduction may precipitate damage that is treatable with TSTs. These conditions or diseases are specifically diagnosed by the tests discussed above, and such testing should be performed in suspected cases of stomach conditions such as gastritis, ulcers, viral and bacterial infections, or neoplasms associated with abnormal signal transduction.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des séquences d'acides nucléiques et d'acides aminés qui identifient et codent un nouvel homologue de la kinase humaine activée par un mitogène (SMAP), exprimée par des cellules stomacales humaines. L'invention concerne également des oligomères pour PCR ou des sondes pour hydridation permettant la détection de séquences nucléotidiques codant pour des molécules de SMAP ou analogue, des molécules antisens par rapport aux séquences nucléotidiques codant SMAP, des tests de diagnostic basés sur des molécules d'acide nucléique codant SMAP, des vecteurs d'expression obtenus par génie génétique et des cellules hôtes pour la production de SMAP purifiée, des anticorps capables de se lier spécifiquement à SMAP purifiée, des anticorps capables de se lier spécifiquement à SMAP, ainsi que des agonistes et des inhibiteurs capables de se fixer d'une manière spécifique au polypeptide SMAP.
EP96923586A 1995-06-28 1996-06-28 Homologue de la kinase humaine activee par un mitogene (map) Withdrawn EP0781336A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US722 1995-06-28
US72295P 1995-06-30 1995-06-30
PCT/US1996/011170 WO1997002347A1 (fr) 1995-06-30 1996-06-28 Homologue de la kinase humaine activee par un mitogene (map)

Publications (1)

Publication Number Publication Date
EP0781336A1 true EP0781336A1 (fr) 1997-07-02

Family

ID=21692739

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96923586A Withdrawn EP0781336A1 (fr) 1995-06-28 1996-06-28 Homologue de la kinase humaine activee par un mitogene (map)

Country Status (6)

Country Link
EP (1) EP0781336A1 (fr)
JP (1) JPH10505510A (fr)
AU (1) AU723640B2 (fr)
CA (1) CA2198729A1 (fr)
MX (1) MX9701596A (fr)
WO (1) WO1997002347A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869043A (en) * 1993-09-17 1999-02-09 Smithkline Beecham Corporation Drug binding protein
EP0932666B1 (fr) 1996-10-09 2004-12-15 Medical Research Council Proteine kinases activees par les mitogenes, polypeptides, polynucleotides et leur utilisation
CA2223075A1 (fr) * 1997-12-02 1999-06-02 Smithkline Beecham Corporation Proteine fixatrice de medicaments
US6897019B1 (en) 1998-04-17 2005-05-24 Tufts College Methods for treating and preventing insulin resistance and related disorders
WO2000006728A2 (fr) * 1998-07-28 2000-02-10 Incyte Pharmaceuticals, Inc. Effecteurs de phosphorylation
US8900811B2 (en) 2000-11-16 2014-12-02 Caliper Life Sciences, Inc. Method and apparatus for generating thermal melting curves in a microfluidic device

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU677834B2 (en) * 1993-04-07 1997-05-08 Cancer Research Ventures Limited Methods for screening of substances for therapeutic activityand yeast for use therein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9702347A1 *

Also Published As

Publication number Publication date
AU6405996A (en) 1997-02-05
JPH10505510A (ja) 1998-06-02
MX9701596A (es) 1997-05-31
AU723640B2 (en) 2000-08-31
CA2198729A1 (fr) 1997-01-23
WO1997002347A1 (fr) 1997-01-23

Similar Documents

Publication Publication Date Title
US5817479A (en) Human kinase homologs
JP4085114B2 (ja) 炎症アデノイドで発現する新規なケモカイン及びその製造と使用
US6190663B1 (en) Human MAP kinase homolog
US5914393A (en) Human Jak2 kinase
AU718269B2 (en) A human EDG-2 receptor homolog
US5587306A (en) Phospholipase C homolog
AU718311B2 (en) A C5a-like seven transmembrane receptor
AU723640B2 (en) A human map kinase homolog
US6534275B1 (en) Cellubrevin homologs
US5780268A (en) Chemokine expressed in a mixed lymphocyte reaction
US20060153852A1 (en) Novel human Jak2 kinase
US5840562A (en) DNA encoding human cysteine protease
WO1997006262A1 (fr) Tyrosine phosphatase proteique derivee de basophiles / mastocytes humains
AU728088B2 (en) Novel human cysteine protease
GB2346882A (en) Human vanilloid receptor-like receptor
US5738991A (en) Method of detecting elastase IV
MXPA97007852A (en) Homologo de fosfolipas

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970324

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE DE ES FR GB IT NL

17Q First examination report despatched

Effective date: 20011019

18D Application deemed to be withdrawn

Effective date: 20041116

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041013